Logo image of BIIB

BIOGEN INC (BIIB) Stock Fundamental Analysis

NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD

131.23  +3.38 (+2.64%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to BIIB. BIIB was compared to 556 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB has a bad growth rate and is valued cheaply. These ratings could make BIIB a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year BIIB was profitable.
In the past year BIIB had a positive cash flow from operations.
In the past 5 years BIIB has always been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

Looking at the Return On Assets, with a value of 5.28%, BIIB belongs to the top of the industry, outperforming 92.27% of the companies in the same industry.
BIIB has a better Return On Equity (8.71%) than 93.70% of its industry peers.
BIIB has a Return On Invested Capital of 9.95%. This is amongst the best in the industry. BIIB outperforms 95.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is below the industry average of 14.97%.
Industry RankSector Rank
ROA 5.28%
ROE 8.71%
ROIC 9.95%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

BIIB has a Profit Margin of 15.07%. This is amongst the best in the industry. BIIB outperforms 93.88% of its industry peers.
In the last couple of years the Profit Margin of BIIB has declined.
BIIB's Operating Margin of 26.30% is amongst the best of the industry. BIIB outperforms 97.12% of its industry peers.
BIIB's Operating Margin has declined in the last couple of years.
The Gross Margin of BIIB (75.58%) is better than 83.45% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 26.3%
PM (TTM) 15.07%
GM 75.58%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

BIIB has an Altman-Z score of 2.74. This is not the best score and indicates that BIIB is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.74, BIIB is doing good in the industry, outperforming 72.30% of the companies in the same industry.
BIIB has a debt to FCF ratio of 2.74. This is a good value and a sign of high solvency as BIIB would need 2.74 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.74, BIIB belongs to the best of the industry, outperforming 94.06% of the companies in the same industry.
BIIB has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
BIIB has a Debt to Equity ratio of 0.27. This is in the lower half of the industry: BIIB underperforms 71.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 2.74
Altman-Z 2.74
ROIC/WACC1.08
WACC9.24%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

A Current Ratio of 1.44 indicates that BIIB should not have too much problems paying its short term obligations.
With a Current ratio value of 1.44, BIIB is not doing good in the industry: 81.83% of the companies in the same industry are doing better.
A Quick Ratio of 1.01 indicates that BIIB should not have too much problems paying its short term obligations.
BIIB has a Quick ratio of 1.01. This is amonst the worse of the industry: BIIB underperforms 86.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.01
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.06% over the past year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 1.59%.
BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)3.06%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%-17.71%
Revenue 1Y (TTM)1.59%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%6.13%

3.2 Future

BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.48% yearly.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.48% yearly.
EPS Next Y-7.3%
EPS Next 2Y-2.23%
EPS Next 3Y0.32%
EPS Next 5Y1.48%
Revenue Next Year-3.86%
Revenue Next 2Y-2.87%
Revenue Next 3Y-1.51%
Revenue Next 5Y-0.48%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 8.30, the valuation of BIIB can be described as very reasonable.
97.84% of the companies in the same industry are more expensive than BIIB, based on the Price/Earnings ratio.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 27.53, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.34, which indicates a very decent valuation of BIIB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.66% of the companies listed in the same industry.
BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.71.
Industry RankSector Rank
PE 8.3
Fwd PE 8.34
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.56% of the companies in the same industry.
98.02% of the companies in the same industry are more expensive than BIIB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.38
EV/EBITDA 6.82
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.23%
EPS Next 3Y0.32%

More info and screens

0

5. Dividend

5.1 Amount

BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOGEN INC

NASDAQ:BIIB (7/23/2025, 3:56:04 PM)

131.23

+3.38 (+2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners92.86%
Inst Owner Change-0.17%
Ins Owners0.13%
Ins Owner Change7.6%
Market Cap19.23B
Analysts73.02
Price Target173.95 (32.55%)
Short Float %2.74%
Short Ratio2.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.97%
Min EPS beat(2)0.67%
Max EPS beat(2)17.28%
EPS beat(4)4
Avg EPS beat(4)13.01%
Min EPS beat(4)0.67%
Max EPS beat(4)28.61%
EPS beat(8)8
Avg EPS beat(8)8.78%
EPS beat(12)12
Avg EPS beat(12)10.47%
EPS beat(16)14
Avg EPS beat(16)9.94%
Revenue beat(2)2
Avg Revenue beat(2)3.39%
Min Revenue beat(2)0.11%
Max Revenue beat(2)6.67%
Revenue beat(4)3
Avg Revenue beat(4)1.89%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)6.67%
Revenue beat(8)5
Avg Revenue beat(8)0.61%
Revenue beat(12)8
Avg Revenue beat(12)1.03%
Revenue beat(16)11
Avg Revenue beat(16)1.28%
PT rev (1m)0.35%
PT rev (3m)-13.35%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)-1.01%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-5.08%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.49%
Valuation
Industry RankSector Rank
PE 8.3
Fwd PE 8.34
P/S 1.96
P/FCF 8.38
P/OCF 7.45
P/B 1.13
P/tB 20.97
EV/EBITDA 6.82
EPS(TTM)15.82
EY12.06%
EPS(NY)15.74
Fwd EY12%
FCF(TTM)15.67
FCFY11.94%
OCF(TTM)17.62
OCFY13.43%
SpS66.99
BVpS115.87
TBVpS6.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.28%
ROE 8.71%
ROCE 11.36%
ROIC 9.95%
ROICexc 11.23%
ROICexgc 55.5%
OM 26.3%
PM (TTM) 15.07%
GM 75.58%
FCFM 23.39%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 2.74
Debt/EBITDA 1.38
Cap/Depr 40.34%
Cap/Sales 2.91%
Interest Coverage 250
Cash Conversion 78.44%
Profit Quality 155.18%
Current Ratio 1.44
Quick Ratio 1.01
Altman-Z 2.74
F-Score6
WACC9.24%
ROIC/WACC1.08
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)3.06%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%-17.71%
EPS Next Y-7.3%
EPS Next 2Y-2.23%
EPS Next 3Y0.32%
EPS Next 5Y1.48%
Revenue 1Y (TTM)1.59%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%6.13%
Revenue Next Year-3.86%
Revenue Next 2Y-2.87%
Revenue Next 3Y-1.51%
Revenue Next 5Y-0.48%
EBIT growth 1Y21.69%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year9.62%
EBIT Next 3Y4.45%
EBIT Next 5Y5.34%
FCF growth 1Y61.56%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y53.87%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%